Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target
Work
Year: 2021
Type: article
Source: Journal of Medicinal Chemistry
Institutions Korea Basic Science Institute, Max Planck Institute for Biophysical Chemistry, Daegu-Gyeongbuk Medical Innovation Foundation, Kyungpook National University, Krea University +1 more
Cites: 66
Cited by: 4
Related to: 10
FWCI: 0.908
Citation percentile (by year/subfield): 80.64
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders Korea Basic Science Institute, Korea Basic Science Institute, Korea Basic Science Institute, Korea Basic Science Institute
Grant IDS C130000, T39632, C140130, C030130